Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1439A versus Atripla in treatment-naive adults with HIV-1
2014-003382-17Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Delstrigo in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Virologic suppression at Week 48 and Neuropsychiatric adverse events by Week 48. Started May 2015; status: completed.
02
Drugs
Delstrigo
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2014-003382-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003382-17.